Artwork
iconShare
 
Manage episode 484124683 series 3649969
Content provided by The Wall Street Journal and Spotify Studios. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Wall Street Journal and Spotify Studios or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.

Further Listening:

Trillion Dollar Shot

Why WeightWatchers Wants in on Drugs Like Ozempic

Sign up for WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices

  continue reading

301 episodes